The FXR agonist PX20606 reduces liver damage, fibrosis and portal hypertension in cirrhotic rats
P Schwabl, E Hambruch, BA Payer, TL Schubert, B Strobel, S Fida, M Wagner, L Garnys, M Trauner, M Peck-Radosavljevic, C Kremoser, T Reiberger · Zeitschrift für Gastroenterologie · 2015 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: FXR agonism attenuates liver injury and cholestatic and metabolic liver disease. We tested the impact of the synthetic FXR agonist PX20606 (PX) on liver histology, inflammation and hemodynamics in a rodent model of toxic cirrhosis. Methods: Cirrhosis was induced by carbontetrachloride (CCl4) administration for 12 weeks in Sprague Dawley rats. Controls received corn-oil. PX (10 mg/kg/day) or placebo were gavaged daily from week 4. Blood was sampled at week 11. After 12 weeks, mean arterial pressure (MAP), heart rate (HR), portal pressure (PP) and superior mesenteric artery blood flow (SMABF) were meas…
